Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PVC2 | ISIN: KYG4783B1032 | Ticker-Symbol: 33C
Tradegate
09.10.25 | 18:38
1,900 Euro
+2,70 % +0,050
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOCARE PHARMA LTD Chart 1 Jahr
5-Tage-Chart
INNOCARE PHARMA LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,5701,68020:54
1,5701,68020:51

Aktuelle News zur INNOCARE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:10Fierce Pharma Asia-TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment2
INNOCARE PHARMA Aktie jetzt für 0€ handeln
13:13INNOCARE (09969): NEXT DAY DISCLOSURE RETURN2
DoChina's InnoCare Plunges After Granting Overseas Rights for Three Innovative Drugs to US Peer Zenas1
MiZenas makes big bet on MS drug, striking $2B licensing deal with InnoCare2
MiZenas climbs on licensing deal with InnoCare2
MiZenas Biopharma licenses three autoimmune candidates from InnoCare1
MiINNOCARE, Zenas Forge Global Strategic Co-op & License Deal with Total Potential Value USD2B+2
MiZenas und InnoCare schließen Lizenzvertrag für MS-Medikament im Wert von 2 Mrd. US-Dollar3
MiZenas, InnoCare ink $2 billion MS drug licensing deal1
MiZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis45- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple...
► Artikel lesen
MiINNOCARE (09969): INSIDE INFORMATION ANNOUNCEMENT - GLOBAL STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ZENAS BIOPHARMA2
22.09.INNOCARE (09969): INTERIM REPORT 20251
08.09.InnoCare Pharma: Singapore Approves HIBRUKA For Treatment Of R/R Marginal Zone Lymphoma In Adults5
08.09.InnoCare Pharma: InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore 76BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA...
► Artikel lesen
20.08.INNOCARE (09969): GRANT OF RESTRICTED SHARE UNITS PURSUANT TO 2023 SHARE AWARD SCHEME2
20.08.INNOCARE (09969): GRANT OF RESTRICTED SHARES PURSUANT TO 2024 RMB SHARE INCENTIVE SCHEME-
19.08.INNOCARE (09969): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 20253
18.08.DMS Group: An International Alliance For European Technological Sovereignty In Medical Imaging - Capital Increase Of A Total Amount Of Eur 6.9 Million Reserved For Innolux, Innocare, Bpifrance And NextStage AM535A major international industrial alliance, supported by major institutional investors. DMS Group, a fast-growing European industrial player, is joining forces with two listed Asian technology...
► Artikel lesen
05.08.INNOCARE (09969): DATE OF BOARD MEETING2
24.07.UBS raises InnoCare Pharma stock price target to HK$25.20 on pipeline potential3
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1